Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Management
Scientific Advisory Board
Corporate Governance
Our Science
Lead Drug Development
Cholesterol-Lowering Program
Brain Injury Program
Technical Glossary
Drug Development Pathway
Investors
Investor Welcome
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Past Shareholder Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Welcome
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Past Shareholder Meetings
ASX Announcements
Filter by Year:
2023
2022
2021
2020
17-May-2022
European Patent to be Granted for Cholesterol-Lowering Drug
19-Apr-2022
Nyrada Quarterly Activities Report & Appendix 4C
30-Mar-2022
Investor Roadshow Presentation
29-Mar-2022
New Drug Offers Potential Oral Treatment for Concussion
2-Mar-2022
Presentation to Meet the CEO Life Sciences Edition
25-Feb-2022
Nyrada Half Year Results FY2022
25-Feb-2022
Appendix 4D and Half Year Report to 31 December 2021
21-Jan-2022
Nyrada Quarterly Activities Report & Appendix 4C
17-Jan-2022
Application for quotation of securities - NYR
17-Jan-2022
Change of Director's Interest Notice - ID
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Next
